Acknowledgements
viral infectious diseases
VIRAL INFECTIOUS DISEASE, AIDS
This work was supported by the Natural Science Foundation of Shanghai (21ZR1475600), Science and Technology Commission of Shanghai Municipality (20431900100), Shanghai Science and Technology Committee (19430750100), National Key R&D Program of China (2016YFA0502301 and 2021YFC2301204), Drug development for the newly emerging viral infectious diseases (SIMM010107), Fundamental Research Funds for the Central Universities (2022ZFJH003), and Zhejiang Provincial Key Research & Development Program of China (2021C03043 and No. 2021C03039). We thank Pfizer Inc. for providing nelfinavir tablets and Hainan Haiyao Co. Ltd. for providing funding to carry out the clinical trial; the departments of Science and Technology, International & Domestic Cooperation, and Technology Transfer in Shanghai Institute of Materia Medica for the aids in the animal study and clinical trial. We also thank Prof. Zhili Zuo in Kunming Institute of Botany for his help in the animal study.